Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
about
Morbidity and mortality associated with obesity.Pharmacokinetics of Antimicrobials in Obese Children.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulationsSemiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic ModelThe Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1)Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Effect of blood protein concentrations on drug-dosing regimes: practical guidance.Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform.High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group.Obesity and its impact on drug therapy: are we ready for this change?Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.Patient-factors associated with metformin steady-state levels in type 2 diabetes mellitus with therapeutic dosage.A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution
P2860
Q33592804-A1816DC8-EADE-420A-8992-9BC082BF520AQ33855312-6641AB7D-9817-4FD2-B77C-28450AC7CBB8Q35560052-D01E45DE-AF66-4060-A2CF-17B6056AFCC3Q36243622-A10D9E70-058E-4BD5-B562-4F42BB139E87Q36506472-0C7FEAD6-1F23-4CC1-873E-11310C66803AQ36910606-5F0B1863-4837-4C19-BCEE-7A910A7E8A79Q36947718-95BE6290-788D-4E31-B3F7-719278E7CCE5Q37062619-ABDCF005-8287-4786-8B7F-FCD9137FE8CBQ38014312-0E3CF115-BCB6-4D3C-8B67-635DC08321E2Q38087695-E9668059-8F53-41C0-9737-D33DAAE5168FQ38620876-CFE8B602-8C5F-49A1-B2DD-9DC8856B877BQ38959281-BF1E4DD2-E4B6-4FA3-AAEB-41B82C25BEA4Q39219941-13CA6A3B-2929-4B9C-A202-886DF85A918FQ41454726-3675332D-2482-4F42-BBB9-5721CD53616FQ41768726-A6A95756-89AD-4060-9467-85A3001261E6Q41839399-9503E3C7-A593-416B-B543-B096FE78FBC2Q45766709-ACF0CC4D-C74D-4FCC-A3B2-99190CB1D502Q46260355-DF4DF579-C883-41E1-9A2F-D429BEF5C40FQ50120162-C5ADEEC8-47E8-4E91-9AED-A33E3C0AD6E7Q55128082-EBDFF7C2-D3E1-41C1-93D5-E1DD1A39CE7BQ57719724-B0237585-A932-4A84-ABA1-A7E58C4E33D8
P2860
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Application of a systems appro ...... ected variations in clearance.
@ast
Application of a systems appro ...... ected variations in clearance.
@en
Application of a systems appro ...... ected variations in clearance.
@nl
type
label
Application of a systems appro ...... ected variations in clearance.
@ast
Application of a systems appro ...... ected variations in clearance.
@en
Application of a systems appro ...... ected variations in clearance.
@nl
prefLabel
Application of a systems appro ...... ected variations in clearance.
@ast
Application of a systems appro ...... ected variations in clearance.
@en
Application of a systems appro ...... ected variations in clearance.
@nl
P2093
P2860
P1476
Application of a systems appro ...... ected variations in clearance.
@en
P2093
Amin Rostami-Hodjegan
Aurel Constant Allabi
Cyrus Ghobadi
Karen Rowland-Yeo
Lisa M Almond
Masoud Jamei
Trevor N Johnson
P2860
P304
P356
10.2165/11594420-000000000-00000
P577
2011-12-01T00:00:00Z
P5875
P6179
1015731657